CA2776310A1 - Pharmaceutical compositions of radezolid and theur use in treting, preventing, or reducing the risk of microbial infections - Google Patents

Pharmaceutical compositions of radezolid and theur use in treting, preventing, or reducing the risk of microbial infections Download PDF

Info

Publication number
CA2776310A1
CA2776310A1 CA2776310A CA2776310A CA2776310A1 CA 2776310 A1 CA2776310 A1 CA 2776310A1 CA 2776310 A CA2776310 A CA 2776310A CA 2776310 A CA2776310 A CA 2776310A CA 2776310 A1 CA2776310 A1 CA 2776310A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
patient
composition according
microbial infection
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2776310A
Other languages
English (en)
French (fr)
Inventor
Eric S. Burak
Danping Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Subsidiary Corp
Original Assignee
Rib X Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rib X Pharmaceuticals Inc filed Critical Rib X Pharmaceuticals Inc
Publication of CA2776310A1 publication Critical patent/CA2776310A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2776310A 2009-10-13 2010-10-12 Pharmaceutical compositions of radezolid and theur use in treting, preventing, or reducing the risk of microbial infections Abandoned CA2776310A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25102309P 2009-10-13 2009-10-13
US61/251,023 2009-10-13
PCT/US2010/052263 WO2011046905A2 (en) 2009-10-13 2010-10-12 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CA2776310A1 true CA2776310A1 (en) 2011-04-21

Family

ID=43876821

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2776310A Abandoned CA2776310A1 (en) 2009-10-13 2010-10-12 Pharmaceutical compositions of radezolid and theur use in treting, preventing, or reducing the risk of microbial infections

Country Status (16)

Country Link
US (2) US20120208857A1 (enExample)
EP (2) EP2488175A4 (enExample)
JP (3) JP2013507443A (enExample)
KR (1) KR101791709B1 (enExample)
CN (1) CN102573840A (enExample)
AU (2) AU2010307054A1 (enExample)
BR (1) BR112012008649A2 (enExample)
CA (1) CA2776310A1 (enExample)
EA (1) EA022765B1 (enExample)
IL (1) IL219018A (enExample)
MX (1) MX337145B (enExample)
NZ (1) NZ599151A (enExample)
PH (1) PH12012500695A1 (enExample)
SG (1) SG10201406571YA (enExample)
UA (1) UA111145C2 (enExample)
WO (1) WO2011046905A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027791B1 (ru) 2010-11-24 2017-09-29 Мелинта Терапьютикс, Инк. Фармацевтические композиции
CN104784113B (zh) * 2015-04-30 2017-09-29 成都国为生物医药有限公司 一种含有利奈唑胺的组合物及其制备方法
US11112370B2 (en) * 2019-01-04 2021-09-07 The Boeing Company Reconfigurable backscatter detector

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
MY127336A (en) * 2000-03-22 2006-11-30 Upjohn Co Container for linezolid iv solution
PE20011088A1 (es) * 2000-03-22 2001-10-04 Upjohn Co Tratamiento de infecciones del tracto urinario con oxazolidinonas antibacterianas
NZ522990A (en) 2000-06-05 2003-08-29 Dong A Pharm Novel oxazolidinone derivatives and a process for the preparation thereof
MY137618A (en) * 2000-08-22 2009-02-27 Pharmacia Corp Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
TWI378092B (en) 2003-06-03 2012-12-01 Rib X Pharmaceuticals Inc Biaryl heterocyclic compounds and methods of making and using the same
US20060270680A1 (en) * 2003-06-03 2006-11-30 Goldberg Joel A Sulfonamide compounds and methods of making and using the same
JP2007514782A (ja) 2003-12-17 2007-06-07 リブ−エックス ファーマシューティカルズ,インコーポレイテッド ハロゲン化ビアリール複素環式化合物ならびにその作製方法および使用方法
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
WO2007086011A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising cefepime, tazobactam and linezolid
WO2007133803A2 (en) * 2006-05-15 2007-11-22 Rib-X Pharmaceuticals, Inc. Treatment of mycobacterial infections
WO2008127300A2 (en) * 2006-10-23 2008-10-23 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
WO2008085913A1 (en) 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections

Also Published As

Publication number Publication date
EP3095445A1 (en) 2016-11-23
PH12012500695A1 (en) 2024-02-12
MX2012004282A (es) 2012-05-22
KR101791709B1 (ko) 2017-10-30
CN102573840A (zh) 2012-07-11
SG10201406571YA (en) 2014-11-27
EA022765B1 (ru) 2016-02-29
KR20120099676A (ko) 2012-09-11
EP2488175A2 (en) 2012-08-22
WO2011046905A3 (en) 2011-10-20
WO2011046905A2 (en) 2011-04-21
EP2488175A4 (en) 2013-08-07
EA201270547A1 (ru) 2012-12-28
IL219018A (en) 2016-11-30
US20120208857A1 (en) 2012-08-16
JP2017141285A (ja) 2017-08-17
AU2010307054A1 (en) 2012-04-26
NZ599151A (en) 2014-07-25
US20150165040A1 (en) 2015-06-18
MX337145B (es) 2016-02-15
JP2013507443A (ja) 2013-03-04
UA111145C2 (uk) 2016-04-11
AU2016234893A1 (en) 2016-10-20
BR112012008649A2 (pt) 2021-11-03
JP2015155479A (ja) 2015-08-27
IL219018A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
AU2016234893A1 (en) Pharmaceutical Compositions
US10300046B2 (en) Pharmaceutical compositions
HK1230972A1 (en) Pharmaceutical compositions comprising radezolid
HK1230972A (en) Pharmaceutical compositions comprising radezolid
US20200237744A1 (en) Antimicrobial Compositions with Effervescent Agents
HK40065457A (en) Antimicrobial compositions with effervescent agents
HK40020067A (en) Antimicrobial compositions with effervescent agents
HK40020067B (en) Antimicrobial compositions with effervescent agents
JP2013507443A5 (enExample)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151007

FZDE Discontinued

Effective date: 20190731